Oncology Market Snapshot
BIOPHARMAWIRE | RESOURCE LIBRARY
Oncology Market Snapshot
Current landscape and competitive analysis across the major oncology indications
Updated Q4 2025 | BioPharmaWire Editors | Sources: company reports, EvaluatePharma, FDA/EMA approvals
Oncology is the largest and most competitive segment in biopharma, accounting for roughly 25% of total drug R&D spend globally and over $200 billion in annual sales. The landscape is shifting rapidly: immuno-oncology remains the dominant platform, but antibody-drug conjugates have emerged as the most dynamic growth area of the past three years, and combinations — IO plus ADC, IO plus targeted therapy — are now the standard architecture for late-stage trial design. This snapshot covers the major solid tumor and haematologic malignancy markets, with competitive positioning and key mechanisms for each.
Market at a Glance
$200B+ global oncology drug market in 2025, projected to exceed $370B by 2030
~1,000 oncology drugs currently in active Phase 2 or Phase 3 trials globally
#1 Keytruda (pembrolizumab) — world’s best-selling drug by revenue, ~$25B in 2024
ADCs fastest-growing drug class in oncology; 14 approved in US/EU as of Q4 2025
~40% of all FDA oncology approvals in 2024 involved a biomarker-selected population
Five Competitive Dynamics Shaping Oncology in 2026
- ADC dominance deepens. Enhertu (trastuzumab deruxtecan) has reshaped HER2-positive breast and lung cancer treatment in under four years, and its success has triggered a wave of ADC development. Over 100 ADCs are now in clinical development. The key question for 2026 is which payload-linker combinations prove durable and which fail on safety.
- PD-1/L1 crowding forces differentiation. The pembrolizumab franchise is enormous but increasingly mature. Newer entrants — BeiGene’s tislelizumab, Junshi’s toripalimab, Akeso’s ivonescimab (PD-1 x VEGF bispecific) — are competing aggressively on combinations and indications not yet covered by Keytruda.
- KRAS finally druggable. Sotorasib and adagrasib opened the KRAS G12C market in NSCLC and colorectal. Next-generation KRAS inhibitors targeting G12D and pan-KRAS, plus combinations with SHP2 and MEK inhibitors, are the most active area of targeted oncology development in 2025-2026.
- Radioligand therapy expands. Novartis’s Pluvicto (lutetium PSMA) has established RLT as a viable platform in prostate cancer. Pipeline programs targeting SSTR2, FAP, and other solid tumor targets are advancing, and manufacturing capacity — the current bottleneck — is being built out aggressively.
- IRA pricing pressure reshapes launch strategy. The Inflation Reduction Act’s Medicare drug price negotiation provisions are altering how US oncology launches are structured, with companies increasingly pricing for shorter exclusivity windows and moving more aggressively into combination indications before the negotiation clock starts.
Oncology Competitive Landscape by Tumor Type
Activity key: Very High High
Tumor Type | 2025 Market | Market Leaders | Key Challengers | Dominant Mechanism | Activity |
SOLID TUMORS | |||||
Non-small cell lung | $28B+ | Merck (Keytruda), AZ (Tagrisso, Imfinzi) | Roche (Alecensa), J&J (Rybrevant) | PD-1/L1, EGFR/ALK TKI | Very High |
Breast cancer | $26B+ | Roche (Herceptin/Perjeta), AZ/Daiichi (Enhertu) | Pfizer (Ibrance), Eli Lilly (Verzenio) | HER2-directed ADC, CDK4/6 | Very High |
Colorectal | $14B+ | Roche (Avastin, Vectibix) | Regeneron (Dupixent CRC), BMS (Opdivo) | VEGF, anti-EGFR, IO | High |
Pancreatic | $4B+ | Ipsen (Onivyde), AZ pipeline | Tempus AI, Relay Therapeutics | KRAS G12C/D, stroma | Very High |
Prostate | $16B+ | J&J (Zytiga/Erleada), Pfizer/Astellas (Xtandi) | Novartis (Pluvicto), AZ (Lynparza) | AR, PARP, RLT | High |
Hepatocellular | $5B+ | Roche (Tecentriq+Avastin), AZ (Imfinzi) | Merck (Keytruda), BMS (Opdivo+Yervoy) | PD-L1 + VEGF combos | High |
Ovarian | $4B+ | AZ (Lynparza), GSK (Zejula) | Clovis (Rubraca), Immunogen (Elahere) | PARP, FRα ADC | High |
Bladder / Urothelial | $6B+ | Pfizer (Padcev), RocheAZ (Imfinzi) | Janssen (Erdafitinib), BMS | ADC + IO combos, FGFR | Very High |
Melanoma | $8B+ | BMS (Opdivo+Yervoy), Merck (Keytruda) | Pfizer (Binimetinib), Iovance (lifileucel) | IO, TIL therapy, BRAF/MEK | High |
HAEMATOLOGIC MALIGNANCIES | |||||
Multiple myeloma | $22B+ | J&J (Darzalex), BMS (Revlimid/Pomalyst) | J&J/Legend (Carvykti), BMS (Abecma) | CD38, BCMA CAR-T, bispecifics | Very High |
Diffuse large B-cell | $6B+ | Kite/Gilead (Yescarta), BMS (Breyanzi) | Roche (Polivy), AbbVie (Venclexta) | CAR-T, BCL-2, bispecifics | High |
CLL / SLL | $10B+ | AbbVie (Imbruvica/Venclexta), AZ (Calquence) | BeiGene (Brukinsa), Lilly (Jaypirca) | BTK, BCL-2 combos | High |
AML | $3B+ | Astellas (Xospata), BMS (Idhifa) | AbbVie/Roche (Venclexta+AZA) | FLT3, IDH1/2, BCL-2 | Very High |
ALL | $2B+ | Novartis (Kymriah), Amgen (Blincyto) | Pfizer (Besylomab), Autolus (Aucatzyl) | CAR-T, BiTE, inotuzumab | High |
Indication Spotlights
Non-Small Cell Lung Cancer
NSCLC is the most commercially significant oncology indication globally, with Keytruda and Tagrisso each generating over $5B annually. The market is bifurcated: biomarker-selected populations (EGFR, ALK, ROS1, KRAS G12C, MET, NTRK) are served by targeted therapies with durable responses; the biomarker-negative or PD-L1-high population is dominated by checkpoint inhibitors, increasingly in combination with chemotherapy or ADCs. The next major competitive battleground is EGFR-mutant NSCLC, where AZ’s Tagrisso faces emerging competition from Rybrevant plus lazertinib (J&J) and next-generation osimertinib combinations.
Breast Cancer
Enhertu has fundamentally changed the HER2-positive treatment paradigm and is now being evaluated across HER2-low and HER2-ultralow populations — a deliberate strategy by AstraZeneca and Daiichi Sankyo to expand the addressable market. CDK4/6 inhibitors (Ibrance, Verzenio, Kisqali) remain the standard of care in HR-positive disease. The key 2026 readout is Verzenio’s adjuvant data in early-stage HR-positive breast cancer and whether it sustains its lead over Ibrance in that setting.
Multiple Myeloma
The most rapidly evolving haematologic malignancy market. Darzalex (daratumumab) has become the backbone of nearly every frontline and relapsed regimen. BCMA-directed CAR-T (Carvykti, Abecma) and bispecific antibodies (teclistamab, elranatamab) are transforming the relapsed/refractory setting. The field is now moving toward earlier-line use of these modalities, with several ongoing trials testing CAR-T in newly diagnosed patients. Sequencing — which therapy in which order — is the defining clinical question for the next two years.
This snapshot is an editorial product of BioPharmaWire based on publicly available data as of Q4 2025. Market size figures are approximate and sourced from publicly available analyst estimates. It does not constitute investment advice. For live coverage of oncology approvals, trial readouts, and deal activity, follow our News and Innovation sections.